Vertex Flooring Presents High-Performance SPC Flooring Designed for Stability, Style, and Durability HOLLISTON, MA, ...

Vertex’s attempt to treat a rare genetic disease has hit another setback. The biotech tossed two more drug candidates onto the discard pile in response to underwhelming data but, following a playbook ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) reported strong Q4 results, reflecting continued execution on its broader portfolio beyond cystic fibrosis. The company is ramping up CASGEVY gene-editing ...

Vertex Pharmaceuticals is paying $420 million upfront to go after the muscular dystrophy market. The outlay will give Vertex ownership of Exonics and expand its deal with CRISPR Therapeutics, setting ...

Vertex Pharmaceuticals will soon try to commercialize another medicine. The new therapy targets the same market as four of its other products. Using a priority review voucher is an expensive choice, ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...

Switzerland-based CRISPR Therapeutics (CRSP) and Boston, Massachusetts-based Vertex (VRTX) have been collaborating together since signing an initial agreement in 2015, with Vertex paying CRISPR $75m ...

Vertex Pharmaceuticals VRTX announced that its triple combination cystic fibrosis (CF) therapy, Kaftrio,has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) ...

Vertex, Inc. (NASDAQ:VERX) Q4 2025 Earnings Call Transcript February 11, 2026 Vertex, Inc. misses on earnings expectations. Reported EPS is $ EPS, expectations were $0.17. Operator: Good day, and ...